Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.

They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.